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ARTICLE OPEN
MiR-221/222 promote epithelial-mesenchymal transition by
targeting Notch3 in breast cancer cell lines
Yuan-Ke Liang1,2,3, Hao-Yu Lin2,4, Xiao-Wei Dou1,2, Min Chen2, Xiao-Long Wei2,5, Yong-Qu Zhang1,2, Yang Wu1,2, Chun-Fa Chen2,4,
Jing-Wen Bai1,2, Ying-Sheng Xiao1,2, Yu-Zhu Qi1,2, Frank A. E. Kruyt3 and Guo-Jun Zhang1,2,6
Basal-like breast cancer (BLBC) is an aggressive subtype with a strong tendency to metastasize. Due to the lack of effective
chemotherapy, BLBC has a poor prognosis compared with luminal subtype breast cancer. MicroRNA-221 and -222 (miR-221/222)
are overexpressed in BLBC and associate with metastasis as well as poor prognosis; however, the mechanisms by which miR-221/
222 function as oncomiRs remain unknown. Here, we report that miR-221/222 expression is inversely correlated with Notch3
expression in breast cancer cell lines. Notch3 is known to be overexpressed in luminal breast cancer cells and inhibits epithelial to
mesenchymal transition (EMT). We demonstrate that miR-221/222 target Notch3 by binding to its 3′ untranslated region and
suppressing protein translation. Ectopic expression of miR-221/222 signiﬁcantly promotes EMT, whereas overexpression of Notch3
intracellular domain attenuates the oncogenic function of miR-221/222, suggesting that miR-221/222 exerts its oncogenic role by
negatively regulating Notch3. Taken together, our results elucidated that miR-221/222 promote EMT via targeting Notch3 in breast
cancer cell lines suggesting that miR-221/222 can serve as a potential therapeutic target in BLBC.
npj Breast Cancer  (2018) 4:20 ; doi:10.1038/s41523-018-0073-7
INTRODUCTION
The majority of breast cancer deaths result from metastatic
disease.1 One of the pivotal processes that induce metastasis of
cancers is the epithelial-to-mesenchymal transition (EMT) by
which epithelial cells are converted to cells with a mesenchymal
phenotype that is associated with enhanced migratory and
invasive properties.2 EMT is considered to be the ﬁrst step in
the complex process of metastasis for many types of cancers.2,3
There have been conﬂicting views about the role of EMT in
metastasis. Based upon the results from genetically engineered
mouse models, some investigators found that EMT is not required
for metastasis but has an important role in chemoresistance,4,5
while others have demonstrated that metastatic dissemination of
mammary tumors indeed depends on EMT programs.6 In another
example, pancreatic carcinoma cells have been shown to utilize
EMT during metastatic dissemination.7
Recently, the discovery of microRNAs (miRNAs), which perform
important regulatory functions in EMT, provides a novel strategy
for the treatment of cancer invasion and metastasis. miRNAs are a
class of small endogenous noncoding RNAs that are involved in
regulating many biological processes by base-pairing with the 3′
untranslated region (UTR) of target messenger RNAs (mRNAs),
resulting in their translational inhibition or degradation.8 Both
miR-221 and miR-222 (miR-221/222), located on the X chromo-
some with the same seed sequences, are highly expressed during
breast tumorigenesis and metastasis.9,10 MiR-221/222 are thought
to serve as oncomiRs because they inhibit many tumor
suppressors, including p27KIP1,11 FOXO3A,12 PTEN, and TIMP3.13
A mutual negative regulatory loop between miR-221/222 and ERα
was also reported by De Leva et al.12 Moreover, miR-221/222
decrease E-cadherin expression by targeting the 3′-UTR of the
GATA family-related TRPS1 (tricho-rhino-phalangeal syndrome
type 1) and induces EMT by negative regulation of ZEB2.14
Overall, miR-221/222 have been shown to promote EMT,
tumorigenesis, and metastasis through multiple mechanisms.
Notch family, including four Notch receptors (NOTCH1,
NOTCH2, NOTCH3 and NOTCH4 (NOTCH1–4)) and ﬁve ligands of
the Delta–Serrate–Lag (DSL) family (jagged 1 (JAG1), jagged 2
(JAG2), delta-like 1 (DLL1), delta-like 3 (DLL3) and delta-like 4
(DLL4)), plays vital roles in many biologic processes, including cell
fate determination, stem cell maintenance, and lineage commit-
ment.15 In human cancers, increasing evidence has demonstrated
that the outcome of Notch activation is dependent on the cancer
type and cellular context.16–19 It has been reported that Notch3 is
speciﬁcally overexpressed in mouse epithelial cells and mammary
luminal progenitor and is required for luminal breast ﬁlling by
inhibiting apoptosis.20,21 Notch3 is elevated in luminal cells and
gives rise to luminal lineages, restricting the proliferation and
consequent clonal expansion of these cells.22 Interestingly, our
previous study found that Notch3 is highly expressed in ER-
positive luminal type compared with triple–negative breast
cancers,23,24 demonstrating its opposite expression pattern to
miR-221/222 in breast cancers. Furthermore, we also provided
Received: 27 January 2018 Revised: 26 June 2018 Accepted: 29 June 2018
1The Breast Center, Cancer Hospital of Shantou University Medical College, 7 Raoping Road, 515031 Shantou, China; 2ChangJiang Scholar’s Laboratory, Shantou University
Medical College, 22 Xinling Road, 515041 Shantou, China; 3Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713
GZ Groningen, The Netherlands; 4Department of Breast and Thyroid Surgery, The First Afﬁliated Hospital of Shantou University Medical College (SUMC), 57 Chang ping Road,
515041 Shantou, China; 5Department of Pathology, The Cancer Hospital of Shantou University Medical College (SUMC), 7 Raoping Road, 515031 Shantou, China and 6Xiang’an
Hospital of Xiamen University, 2000 East Xiang’an Rd., Xiamen, China
Correspondence: G-J. Zhang (gjzhang@xah.xmu.edu.cn)
These authors contributed equally: Yuan-Ke Liang, Hao-Yu Lin
www.nature.com/npjbcancer
Published in partnership with the Breast Cancer Research Foundation
evidence for a pivotal role of Notch3 in the suppression of EMT
and metastasis via trans-activating ERα in breast cancers.23,24
It is well-established that a single miRNA usually regulates a
large set of target genes. It is likely that miR-221/222 target other
genes that are involved in tumorigenesis and metastasis. In the
current study, we demonstrated that Notch3 is a novel target of
miR-221/222 which directly bind to its 3′UTR inhibiting its
translation. We further validated that miR-221/222 suppress
Notch3, ERα, and E-cadherin-induced EMT. These results indicate
vital, multi-functional roles of miR-221/222 in the promotion of
EMT in breast cancer.
RESULTS
Notch3 is overexpressed in luminal breast cancer cells and has an
inverse correlation with miR-221/222
Our earlier study has revealed that Notch3 maintained luminal
phenotype and suppresses tumor metastasis in breast cancer. As
shown in Fig. 1a, high levels of Notch3 mRNA were speciﬁcally
expressed in the ERα-positive luminal breast cancer cell lines MCF-
7 and T-47D, but not in the ERα-negative breast cancer cell lines
MDA-MB-231, BT-549 and SK-BR-3., Western blotting showed that
both full-length and intracellular domain (ICD) of Notch3 were
mainly expressed in luminal epithelial phenotype MCF-7 and T-
47D cell lines, as shown by increased ERα and E-cadherin
expression (Fig. 1b). However, Notch3 expression was not
detected in the basal-like breast cancer cell lines MDA-MB-231,
BT-549, and SK-BR-3, which express the mesenchymal marker
vimentin (Fig. 1b).
To investigate the mechanism of Notch3 down-regulation in
basal-like breast cancer cell lines, we performed bioinformatic
searches (including Pictar, DIANAmT, miRanda, miRWalk and
RNAhybrid databases) to identify putative microRNAs targeting
Notch3. Among the candidate microRNAs identiﬁed, the 3′-UTR of
human Notch3 contains regions that match the seed sequences of
hsamiR-221 and hsamiR-222 (Fig. 1c, d). Furthermore, we
examined the endogenous levels of miR-221/222 by qRT- PCR.
The expression of both miRNAs was almost undetectable in
luminal MCF-7 and T47D breast cancer cells, but miR-221/222
were highly expressed in the basal-like subtypes SKBR3, MDA-MB-
231, and BT549 cells (Fig. 1e). Since our data showed an inverse
correlation between miR-221 or miR-222 and Notch3 expression in
breast cancer cells, we speculated that Notch3 might be a target
of miR-221/222.
MiR-221/222 suppress Notch3 protein expression and induce EMT
To examine miR-221 and miR-222’s roles in regulating Notch3 and
EMT, we transfected synthetic oligo mimics for miR-221 and miR-
222 into MCF-7 breast cancer cells. Expression of both miRNAs was
increased around 1000-fold after 48 h of transfection with the
mimics (Fig. 2a). Using qRT-PCR, we found that Notch3 mRNA level
did not change in miR-221 or miR-222 transfected cells compared
with the control group (Fig. 2b). In contrast, overexpressing miR-
221/222 signiﬁcantly decreased endogenous Notch3 (both full
length and ICD), ERα, p27, and E-cadherin protein levels (Fig. 2c).
Conversely, the addition of miR-221/222 inhibitors to MDA-MB-
231 cells (Fig. 2d) signiﬁcantly induced Notch3 ICD and E-cadherin
expression while vimentin expression signiﬁcantly decreased. The
p27, and ERα known to be miR221/222 targets, was also
upregulated by miR-221/222 inhibition as expected (Fig. 2f).
Intriguingly, Notch3 mRNA levels did not change in miR-221/222
inhibitor-transfected cells (Fig. 2e), indicating that miR-221/222
regulate Notch3 only at the translational level. To further conﬁrm
miR221/222’s role in regulating Notch3, we transiently transfected
MCF-7 cells with pcDNA6.2-GW/EmGFP-miR-221/222 as well as the
empty pcDNA6.2-GW/EmGFP vector. Immunoﬂuorescence stain-
ing showed that Notch3 levels were largely reduced in cells
expressing miR-221/222 compared with cells transfected with GFP
alone or the untransfected cells (Fig. 2g).
MiR-221 and miR-222 directly target Notch3 3′UTR to inhibit
Notch3 expression
To verify that Notch3 is a direct target of miR-221/222, the wild
type (WT) Notch3 reporter pMIR-Notch3-3′UTR WT or control
reporter was co-transfected with agomiR221/222 (mimics) in MCF-
7 cells that express low levels of miR-221 and miR-222 (Fig. 3a). As
expected, both agomiR-221 and agomiR-222 decreased luciferase
activities of the Notch3 reporter by about 50~80% in MCF-7 cells
in a dose-dependent manner, while the control reporter was not
affected (Fig. 3b, c). Similarly, luciferase activities were also
reduced by agomiR-221/222 as visualized by bioluminescent
imaging and following quantiﬁcation (Fig. 3d–g). To further
examine whether miR-221/222 directly regulates Notch3 by
targeting the GTGTAGCT seed binding site, we co-transfected
pMIR-Notch3 3′UTR WT or mutated reporters with miR-221/222
mimics and inhibitors (antagomiR-221/222) at the indicated
concentrations in MCF-7 cells. Interestingly, the dose-dependent
inhibitory effect of miR-221/222 on Notch3 3′UTR activity was
rescued by co-expression of miR-221/222 inhibitors. However, no
signiﬁcant changes in luciferase activity were seen when using the
Notch3 3′UTR mutant reporter (Fig. 3h, i). In contrast, miR-221/222
inhibitors increased luciferase activity in MDA-MB-231 cells in a
dose-dependent manner when co-transfected with a pMIR-
Notch3-3′UTR WT reporter. Increased luciferase activity was
reversed when co-expressed with miR-221/222 mimics (Fig. 3j,
k). In summary, these results support the bioinformatic prediction
that Notch3 is a direct target of miR-221 and miR-222.
MiR-221/222 induce EMT through downregulation of Notch3
To determine the effects of miR-221 and miR-222 on EMT, we
established MCF-7 cells stably transfected with GFP-miR-221 or
GFP-miR-222 plasmids. Western blot analysis revealed that over-
expression of miR-221 or miR-222 downregulated Notch3, ERα,
and E-cadherin expression in MCF-7 cells (Fig. 4a). Subsequently,
we examined whether overexpression of miR-221/222 induced
morphological changes associated with EMTs in MCF-7 cells. Both
miR-221- and miR-222-transfected MCF-7 cells displayed
ﬁbroblast-like morphologies and showed cellular scattering
compared with the control cells, which maintained a cobblestone
phenotype with strong cell-cell adhesion (Fig. 4b). Next, we
investigated whether miR-221 and miR-222 affect cellular migra-
tion and invasion in breast cancer cells. It had been reported that
miR-221/222 promote proliferation in human cancers. To eliminate
these impacts, serum free medium was used in wound healing
assay and transwell assay (Supplementary Figure 1A–D). In a
wound healing assay, miR-221 or miR-222 overexpression in MCF-
7 cells resulted in an approximately 2-fold increase in the cell
migration rate compared with the control group after 48 h in
culture (Fig. 4c, d and Supplementary Figure 1E). Moreover,
matrigel-coated (for invasion) or uncoated (for migration)
Transwell assays showed that miR-221 and miR-222 overexpres-
sion drastically increased the migration (about 2-folds) and
invasiveness (5-folds) of the MCF-7 cell line; when overexpressing
N3ICD by transient transfection, the increases in invasion and
migration were almost completely suppressed (Fig. 4e–h).
Conversely, expressing miR-221 or miR-222 inhibitors in MDA-
MB-231 cells decreased the migration rate by about 50%
compared with the control group after 24 h (Fig. 5a, b). MDA-
MB-231 cells treated with either miR-221 or miR-222 inhibitor
showed signiﬁcantly decreased migratory and invasive abilities
compared to control cells (Fig. 5c, d). These results conﬁrm that
miR-221 and miR-222 promote migration and invasion through
inhibition of Notch3 expression.
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MicroRNAs are attractive and effective drug targets as they
regulate many important cellular processes and are differentially
expressed in malignancies compared with normal tissues.
Numerous miRNAs have been shown to have altered expression
in a variety of human cancers and function as oncomiRs or tumor
suppressors.25–27 For example, constitutive up-regulation of miR-
221/222 contributes to poor prognosis in various types of tumors,
including hepatocarcinoma, colon, breast, pancreas and lung
cancers.12,13,28,29 In breast cancer, miR-221/222 was more abun-
dant in basal-like tumors than in ER/PR–positive tumors14 which in
line with our previous ﬁndings. It has been demonstrated that
miR-221 and miR-222 each directly target ERα mRNA at a
conserved site and are involved in anti-estrogen resistance.12,30–
32 Our previous study also revealed that Notch3 trans-activated
ERα and inhibited EMT and metastasis in breast cancer.23
In the present study, we attempted to identify potential targets
regulated by miR-221/222. Consistent with our previous ﬁndings,
elevated expression of miR-221 and/or miR-222 in basal-like/
mesenchymal/ER-negative breast cancer cells compared to
luminal/epithelial/ERα-positive cells was detected by RT-PCR.12
Notch3 was elevated in ER-positive breast cancer cells, indicating
that miR-221/222 could be a causal factor in the downregulation
of Notch3. This notion was further conﬁrmed by the observation
that Notch3 was signiﬁcantly inhibited in ERα-positive breast
cancer cells treated with miR-221/222 mimics in a dose-
dependent manner. Conversely, overexpression of miR-221/222
inhibitors upregulated Notch3 expression and downstream
proteins, such as ERα and E-cadherin. Also, the fact that Notch3
mRNA was not affected by either mimics or inhibitors suggests
that miR-221/222 directly binds to Notch3 transcripts without
leading to its degradation. This ﬁnding is consistent with a
previous report showing that miR-221/222 can suppress the
Fig. 1 miR-221/222 have an inverse correlation with Notch3 in breast cancer cells. a qRT-PCR analysis of Notch3 mRNA expression in breast
cancer cell lines. b Endogenous Notch3 full length (FL) and the intracellular domain (ICD), ERα, E-cadherin, and Vimentin protein levels in
breast cancer cell lines. c, d Databases to predict miR-221/222 target genes and sequence alignment of the human miR-221 and miR-222 seed
regions with Notch3 3′UTR, which contains predicted miR-221/222 binding site. e qRT-PCR analysis of miR-221/222 expression in breast cancer
cell lines
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Fig. 2 Notch3 is a target of miR-221/222 in breast cancer cells. a MiR-221 and miR-222 expression levels were detected by qRT-PCR after
forced transfection of miR-221 or miR-222 mimics in MCF-7 cells. b qRT-PCR of Notch3 mRNA after forced transfection of miR-221 and miR-222
mimics in MCF-7 cells. c Western blot analysis of endogenous Notch3, ERα, p27 and E-cadherin protein levels in MCF-7 cells after ectopic
expression of miR-221/222 mimics in MCF-7 cells. d, e qRT-PCR of endogenous miR-221/222 and Notch3 mRNA in MDA-MB-231 cells after
transfection with miR-221/222 inhibitors. f Western blot analysis of N3FL, N3ICD, ERα, p27, and Vimentin protein levels after transfection with
miR-221/222 inhibitors in MDA-MB-231 cells. g Immunoﬂuorescence staining of MCF-7 cells transiently transfected with GFP vector
(expressing only GFP), GFP-miR-221 or GFP-miR-222 using an anti-Notch3 antibody. Notch3 signals (red) in miR-221 and miR-222-transfected
cells are labeled with arrowheads. DAPI, 4′,6-diamidino-2-phenylindole
MiR-221/222 promote epithelial-mesenchymal transition by targeting
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Fig. 3 MiR-221/222 directly target Notch3 3′UTR. a The schematic luciferase reporter containing predicted Notch3 wild-type (WT) or its
mutant 3′UTR sequences for miR-221/222. b, c MCF-7 cells were co-transfected with pMIR-Notch3-3′UTR WT or pMIR control reporters in the
presence of agomiR-221/222 (10, 30, and 90 nM) or miR-control (NC). Fluc/Rluc activities were measured 48 h post-transfection and normalized
to the corresponding vector control. Each transfection was performed in triplicate, and the experiment was repeated three times. Data
represent the mean ± SEM. ***P < 0.001. d, e MCF-7 cells stably transfected with pMIR-Notch3-3′UTR were treated with agomiR-221/222 at the
indicated concentrations or pMIR-control vector, and luciferase activities were detected 48 h after transfection by a molecular imaging device
(IVIS KINETIC). f, g Quantitation of luciferase activities when transfected with agomiR-221 and agomiR-222 in IVIS KINETIC system. h, i MCF-7
cells were co-transfected with pMIR-Notch3-3′UTR wild-type (WT) or pMIR-Notch3-3′UTRmutant (Mutant) reporters in the presence of agomiR-
221/222 (10, 30 nM) and antagomiR-221/222 (10, 30 nM) or miR-control (NC). Fluc/Rluc activities were measured 48 h post-transfection and
normalized to the corresponding vector control. j, kMDA-MB-231 cells were co-transfected with pMIR-Notch3-3′UTR reporters in the presence
of antagomiR-221/222 (10, 30 nM) and agomiR-221/222 (10, 30 nM) or miR-control (NC). Fluc/Rluc activities were measured 48 h post-
transfection and normalized to the corresponding vector control. Each transfection was performed in triplicate, and the experiment was
repeated three times. Data represent mean ± SEM
MiR-221/222 promote epithelial-mesenchymal transition by targeting
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Fig. 4 N3ICD overexpression reverses EMT promotion by miR-221 and miR-222 in MCF-7 cells. a Western blot shows that MCF-7 cells that
were stably transfected with GFP-miR-221 and GFP-miR-222 vectors suppressed Notch3 ICD and ERα as well as E-cadherin. b Effect of miR-221/
222 overexpression on cell morphology evaluated by phase contrast microscopy (×100). Scale bars represent 50 μm. c, d Representative
micrographs (×40) of the wound healing assay in MCF-7 cells. Cells were photographed to measure wound length at 0 and 48 h. Wound
healing lengths were measured in 5 random ﬁelds. Data represent the mean of triplicate experiments ± SEM. e–h Representative micrographs
(×200) of migration and invasion Transwell assays. Stably transfected miR-221/222 MCF-7 cells were co-transfected with N3ICD or a control
plasmid. Invading or migrating cells were counted in 5 random ﬁelds. Data represent the mean of triplicate experiments ± SEM. Scale bars
represent 50 μm
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expression of targeted proteins without altering their mRNAs.13
Hence, we do believe that the low Notch3 mRNA and protein
expressions in basal-like breast cancer cells are not just because of
the abundant of miR-221/222 but a complex regulatory network.
MiR-221/222 have been shown to increase migration and
invasion by targeting PTEN and p27 indicating their potential
mechanistic link to EMT.11,13 MiR-221/222 also target the 3′UTR of
various genes, including those encoding estrogen receptors (ESR1)
and TRPS1. It had been reported that miR-221/222 could directly
bind to the ERα-3′UTR and suppress its expression, on the other
hand, ERα also could directly represses miR-221 and -222 by
recruiting the corepressors NCoR and SMRT.12 In addition, forced
expression of ERα repressed Slug, up-regulated E-cadherin, and
induced cells to grow as adherent colonies with reduced
invasiveness.33 What’s more, over-expression of miR-221/222
decrease E-cadherin through targeting the 3′UTR of the GATA
family-related TRPS1, which represses ZEB2 expression.14 Thus,
there seem a complex regulatory network between miR-221/222,
ERα, and E-cadherin. Therefore, it’s not clear if miR-221/222
regulated ER and E-cadherin independently or not. At least, miR-
221/222 could regulate E-cadherin either independent or depen-
dent on ERα regulation. To investigate the functional signiﬁcance
of Notch3/ERα regulation by miR-221/222, we performed the
migration, invasion, and wound healing assays using mimics or
inhibitors against miR-221 and/or miR-222. As expected, addition
of inhibitors to mimics or addition of mimics to inhibitors reversed
their biological functional effects on migration, invasion, and
wound healing. The observation that the overexpression of miR-
221/222 induces migration and invasion provides functional
evidence for the possible role of these miRNAs in breast cancer.
The invasive potential of miR-221/222 was strongly blocked by the
ectopic expression of Notch3 ICD, indicating that miR-221/222
promote EMT, at least partially, through targeting Notch3.
Our ﬁndings have uncovered the regulatory network of miR221/
222 and the underlying mechanism for their functional roles as
oncomiRs in breast cancer cell lines. The data presented in this
study highlight a mechanism by which miR-221/222 promote
migration and invasion by targeting Notch3 in breast cancer cell
lines. Our results suggest that targeting miR-221 and miR-222
represents an effective strategy to prevent and inhibit tumor
progression and metastasis in breast cancer.
MATERIALS AND METHODS
Cell culture and transfection
MCF-7, T47D, SKBR3, BT549, and MDA-MB-231 cell lines were purchased
from and validated by American Type Culture Collection (ATCC, VA, USA)
and cultured in DMEM medium, supplemented with 10% FCS. All cells
were cultured at 37 °C in a humidiﬁed 5% CO2 atmosphere. The
oligonucleotides sequences of the miR-221/222 inhibitors, miR-221/222
mimics, agomiR-221/222, antagomiR-221/222 (displayed in Supplementary
Table S1) were transfected by Lipo2000. The plasmids of pcDNA6.2-GW/
EmGFP-miR-221/222 were obtained from Professor Cheng32 (H. Lee Mofﬁtt
Cancer Center and Research Institute). The plasmids of pCLE-N3ICD
(#26894) and control vector pCLE (#17703) were purchased from Addgene
(MA, USA). The vectors containing these oligonucleotides sequences were
transfected into MCF7 cell line by using Lipo2000. Ten μg/ml Blasticidin S
was added to the medium after 2 days in culture for selection.
RNA puriﬁcation and real-time PCR analysis
Total RNA containing small RNAs was extracted from cancer cells using
Trizol total RNA isolation reagent (Invitrogen, CA, USA) according to the
manufacturer’s instructions. cDNA was synthesized from total RNA using
PrimeScript RT reagent Kit (Takara, Japan) according to the protocol.
Quantitative real-time PCR was performed with a SYBR Select Master Mix
(Thermo Fisher, MA, USA) and the CFX96 Real-time PCR Detection System
(Bio-Rad, CA, USA). MicroRNA real-time transcription-PCR quantiﬁcation of
Fig. 5 Inhibition of miR-221/222 decreases migration and invasion ability in MDA-MB-231 breast cancer cells. a, b Representative panels from
the scratch wound assay in MDA-MB-231 cells imaged by microscopy. MDA-MB-231 cells were transfected with a miR-221/222 inhibitor or
miR-control. Wound healing was measured in 5 random ﬁelds. Data represent the mean of triplicate experiments ± SEM. c, d Representative
micrographs (×200) of matrigel-coated or non-coated Transwell assays in MDA-MB-231 cells transfected with miR-221/222 inhibitors or miR-
NC. Cells were photographed to measure wound length at 0 and 24 h. Invading or migrating cells were counted in ﬁve random ﬁelds. Data
represent the mean of triplicate experiments ± SEM. Scale bars represent 50 μm. *P < 0.05; **P < 0.01; ***P < 0.001
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miRNA expression was carried out using a Hairpin-it miRNAs RT-PCR
Quantitation Kit and TaqMan-microRNA assay kit (GenePharma, Suzhou,
China) according to the manufacturer’s protocol. U6 was used for
normalization. Primer sequences are listed in the Supplementary Table S1.
Western blot analysis
Protein extraction and Western blotting were performed as described
previously.34 Brieﬂy, cells were harvested in RIPA lysis buffer (Millipore,
USA). Protein lysates were electrophoresed in polyacrylamide gels and
transferred to PVDF membranes. After blocking in 5% skim milk, the
membranes were incubated with primary antibodies overnight at 4 °C. The
secondary antibody was diluted 1:3000 in fresh blocking solution. The blots
were visualized using the X-OMAT ﬁlm (Kodak, Japan). All blots were
derived from the same experiment and processed in parallel. Primary
antibodies are listed in Supplementary Table S2.
Wound healing assay
Cells were starved in serum-free medium for 24 h before injury lines were
applied. The injury line was made with a tip 2 mm wide on cells plated in
culture dishes at 90% conﬂuency. After rinsing with phosphate-buffered
saline, cells were allowed to migrate in serum-free medium. Photographs
were taken (×40) after 24 h (MDA-MB-231) or 48 h (MCF-7). An average of
ﬁve random widths of injury lines were measured for quantitation.
Transwell assay
Cells were serum-starved for 24 h before seeding in Matrigel-coated/
uncoated chambers (8μm pore size, BD Bioscience, USA). 5 × 104 MCF-7
cells or 2 × 104 MDA-MB-231 cells were seeded in the upper chamber with
serum-free medium. Complete medium was added to the bottom
chamber. After 48 h cell culturing, cells were stained with 0.1% crystal
violet. Each assay was performed in triplicate. Cells from ﬁve ﬁelds in each
well were counted by two investigators.
Dual-luciferase reporter assays
Luciferase activities were detected by using dual luciferase reporter assay
kit (Promega, WI, USA). The 3′UTR or mutated 3′UTR of the Notch3 gene
was cloned between SpeI/HindIII sites of the luciferase reporter vector
pMIR (pMIR-Notch3-3′UTR was kindly provided by Prof. Paola Zanovello,
University of Padova35). pRL-SV40 (Promega, WI, USA) was used as the
control vector to balance transfection efﬁciency. To detect the regulation
of Notch3 mRNA by miR221/222, pMIR-Notch3-3′UTR-wt or pMIR-Notch3-
3′UTR-mut were co-transfected into MCF-7 or MDA-MB-231cells with
different doses of miR221 mimics and/ or miR221 inhibitors.
Statistical analysis
Data were statistically analyzed using two-sided Student’s t-test. P < 0.05
was considered statistically signiﬁcant. Data are shown as mean ± s.e.m.
unless otherwise stated.
Data availability
All data supporting our ﬁndings can be found in the main paper or in
supplementary ﬁles.
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